XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
X4 Pharmaceuticals, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.75+0.16 (+6.18%)
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.22 (−7.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
X4 Pharmaceuticals, Inc grew revenue 86.0% to $8.67M over the twelve months to Jun 30, 2026. Free cash flow was -$85.62M.
Revenue
$8.67M
+86.0% vs. a year earlier
Operating income
-$87.91M
TTM Q2 2026
Free cash flow
-$85.62M
FY2025
EPS, diluted
-$1.87
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $347.45M
- P/E ratio
- –
- Price to sales
- 40.09
- Price to book
- 2.24
- Dividend yield
- –
- Free cash flow yield
- -24.64%
Fundamentals
- Revenue
- $8.67M
- Net income
- -$90.14M
- EPS, diluted
- -$1.87
- Free cash flow
- -$85.62M
- Book value per share
- $1.23
- Diluted shares
- 126M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$8.67M+86.0% YoY
Gross profit
$5.74M
Operating income
-$87.91M
Net income
-$90.14M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months